Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery

Blood

Volumn 108, Issue 8, 2006, Pages 2827-2835

  Dou, Huanyu ^b   Destache, Christopher J ^b   Morehead, Justin R ^b   Mosley, R Lee ^b   Boska, Michael D ^b   Kingsley, Jeffrey ^b   Gorantla, Santhi ^b   Poluektova, Larisa ^b   Nelson, Jay A ^b   Chaubal, Mahesh ^b   Werling, Jane ^b   Kipp, James ^b   Rabinow, Barrett E ^b   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NANOMATERIAL; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; DRUG DELIVERY SYSTEM; HISTOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MALE; MOUSE; NANOPARTICLE; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DISEASE MODEL; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; SCANNING ELECTRON MICROSCOPY; TISSUE DISTRIBUTION; TRANSPLANTATION; ULTRASTRUCTURE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, ELECTRON, SCANNING; NANOSTRUCTURES; NANOTECHNOLOGY; TISSUE DISTRIBUTION;

EID: 33750611615     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-012534     Document Type: Article

References (51)

1. Dam Nielsen S, Kjaer Ersboll A, Mathiesen L, Nielsen JO, Hansen JE. Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. J Infect Dis. 1998;178:1299-1305.
2. Pezzotti P, Napoli PA, Acciai S, et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies: Tuscany AIDS Study Group. Aids. 1999;13:249-255.
3. Sharland M, Watkins AM, Dalgleish AG, Cammack N, Westby M. Immune reconstitution in HAART-treated children with AIDS: Highly Active Anti-Retroviral Therapy. Lancet. 1998;352:577-578.
4. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. The global impact of HIV/AIDS. Nature. 2001;410:968-973.
5. Anabwani G, Navario P. Nutrition and HIV/AIDS in sub-Saharan Africa: an overview. Nutrition. 2005;21:96-99.
6. Chakraborty R. HIV-1 infection in children: a clinical and immunologic overview. Curr HIV Res. 2005;3:31-41.
7. Chen RY, Westfall AO, Raper JL, et al. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Res Hum Retroviruses. 2002;18:909-916.
8. Chulamokha L, DeSimone JA, Pomerantz RJ. Antiretroviral therapy in the developing world. J Neurovirol. 2005;11(suppl 1):76-80.
9. Poluektova LY, Munn DH, Persidsky Y, Gendelman HE. Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol. 2002;168:3941-3949.
10. Petit F, Fromenty B, Owen A, Estaquier J. Mitochondria are sensors for HIV drugs. Trends Pharmacol Sci. 2005;26:258-264.
11. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001;358:1322-1327.
12. Hawkins T. Appearance-related side effects of HIV-1 treatment. AIDS Patient Care STDS. 2006;20:6-18.
13. Delaugerre C, Peytavin G, Dominguez S, et al. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). J Med Virol. 2005;77:345-350.
14. Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem. 2005;12:1705-1719.
15. Duval X, Peytavin G, Albert I, et al. Determination of indinavir and nelfinavir through plasma concentration efficacy thresholds according to virological response in HIV-infected patients. HIV Med. 2004;5:307-313.
16. Alos L, Navarrete P, Morente V, et al. Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. Mod Pathol. 2005;18:127-136.
17. Murri R, Lepri AC, Cicconi P, et al. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian Cohort of Antiretroviral-Naive Patients Study. J Acquir Immune Defic Syndr. 2006;41:23-30.
18. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir. 2005;21:10644-10654.
19. Langmann P, Zilly M, Weissbrich B, Desch S, Vath T, Klinker H. Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. Infection. 2002;30:13-16.
20. Rhame FS, Rawlins SL, Petruschke RA, et al. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:4200-4208.
21. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL.A24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). Aids. 1996;10:485-492.
22. Pan SC, Hsieh SM, Hung CC, Huang PF, Chen MY, Chang SC. Dose reduction for the management of indinavir-related toxicity in human immunodeficiency virus type 1-infected patients in Taiwan: clinical and pharmacokinetic assessment. J Microbiol Immunol Infect. 2005;38:31-34.
23. Poluektova L, Gorantla S, Faraci J, Birusingh K, Dou H, Gendelman HE. Neuroregulatory events follow adaptive immune-mediated elimination of HIV-1-infected macrophages: studies in a murine model of viral encephalitis. J Immunol. 2004;172:7610-7617.
24. Vasudevachari MB, Zhang YM, Imamichi H, Imamichi T, Falloon J, Salzman NP. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob Agents Chemother. 1996;40:2535-2541.
25. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 1997;71:6662-6670.
26. Servais J, Peytavin G, Arendt V, et al. Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance. Aids. 2001;15:941-943.
27. Gonzalez LM, Aguiar RS, Afonso A, et al. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. J Gen Virol. 2006;87:1303-1309.
28. Gallego O, de Mendoza C, Perez-Elias MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. Aids. 2001;15:1701-1706.
29. Gorantla S, Santos K, Meyer V, et al. Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J Virol. 2005;79:2124-2132.
30. Jain KK. The role of nanobiotechnology in drug discovery. Drug Discov Today. 2005;10:1435-1442.
31. Jain KK. Nanotechnology-based drug delivery for cancer. Technol Cancer Res Treat. 2005;4:407-416.
32. Michaelis M, Matousek J, Vogel JU, et al. Bovine seminal ribonuclease attached to nanoparticles made of polylactic acid kills leukemia and lymphoma cell lines in vitro. Anticancer Drugs. 2000;11:369-376.
33. Xing X, He X, Peng J, Wang K, Tan W. Uptake of silica-coated nanoparticles by HeLa cells. J Nanosci Nanotechnol. 2005;5:1688-1693.
34. Varela MC, Guzman M, Molpeceres J, del Rosario Aberturas M, Rodriguez-Puyol D, Rodriguez-Puyol M. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur J Pharm Sci. 2001;12:471-478.
35. Chan WC. Bionanotechnology progress and advances. Biol Blood Marrow Transplant. 2006;12:87-91.
36. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 2002;19:1-72.
37. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst. 2003;20:357-403.
38. Vinogradov S. The second annual symposium on nanomedicine and drug delivery: exploring recent developments and assessing major advances: 19-20 August 2004, Polytechnic University, Brooklyn, NY, USA. Expert Opin Drug Deliv. 2004;1:181-184.
39. Jain KK. Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat. 2005;4:645-650.
40. Pandey R, Ahmad Z, Sharma S, Khuller GK. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm. 2005;301:268-276.
41. Jiao Y, Ubrich N, Marchand-Arvier M, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation. 2002;105:230-235.
42. Ahlin P, Kristl J, Kristl A, Vrecer F. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm. 2002;239:113-120.
43. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci. 2003;92:1085-1094.
44. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb). 2003;83:373-378.
45. Tonnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm. 2002;28:621-630.
46. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21:387-422.
47. Horisawa E, Kubota K, Tuboi I, et al. Size-dependency of DL-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm Res. 2002;19:132-139.
48. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11:413-424.
49. Dou H, Destache C, Kingsley J, et al. A macrophage nanoparticle system for anti-retroviral drug delivery. Paper presented at the 12th Annual Meeting of the Society on Neuroimmune Pharmacology. April 6, 2006. Santa Fe, NM.
50. Kibuule D, Dou H, Ubert M, et al. Magnetic labeled macrophages migrate across the blood brain barrier in mice with HIV-1 encephalitis. Paper presented at the 12th Annual Meeting of the Society on Neuroimmune Pharmacology. April 6, 2006. Santa Fe, NM.
51. Dou H, Morehead JR, Destache CJ, et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology. In press.